BusinessAI imageFDA Decision on Zilurgisertib for Rare Bone Disease Expected September 26
Mirum and Incyte await the FDA's ruling on zilurgisertib, a once-daily pill designed to treat an ultra-rare bone disease. The decision, expected on September 26, could impact the recent stock gains of both companies. This FDA evaluation is critical for the drug's approval and future market performance.
Asianet Newsable·


